Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual...
Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)
CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical study...
Harbour BioMed Reports Full Year 2024 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors
CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a...
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan...
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC
CHENGDU, China, Jan. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NMPA) for the...
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an...
Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC
CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NMPA) for the first...
Kelun-Biotech Announces Interim Results for 2023: Global Strategic Partnership and Rich Pipeline Boost Significant Revenue Growth in the First Half of the Year
CHENGDU, China, Aug. 28, 2023 /PRNewswire/ -- Today, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990.HK), an innovative biopharmaceutical company focusing on the R&D, manufacturing, commercialization, and...